The survival period of glioma patients depends not only on the histological manifestations, resection scope and radiotherapy status, but also on the molecular characteristics including IDH mutation, 1p19g coding deletion, chromosome 10 deletion and PTEN mutation. This evidence concerns the gene PTEN and central nervous system cancer.